Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Transdermal Therapeutics Inc.
483
•Transdermal Therapeutics Inc.•June 27, 2014

Transdermal Therapeutics Inc. – FDA 483, Jun 27, 2014

Record Details

The FDA Form 483 details multiple deficiencies observed during an inspection. The facility fails to conduct appropriate laboratory testing for identity and strength of each active ingredient in drug products prior to release, specifically lacking potency testing for each active ingredient per lot/batch.

There are no written procedures for production and process controls, and the manufacturing process has not been validated to assure identity, strength, quality, and purity. The facility accepts supplier reports of analysis for components without performing at least one specific identity test or validating supplier analyses, and does not conduct additional raw material testing or verify Certificates of Analysis.

Complaint handling procedures are deficient, lacking provisions for quality control review of specification failures, investigation of unexplained discrepancies, and determination of reasons for batch failures. Investigations do not extend to other batches or associated components, and procedures do not address reporting serious and unexpected adverse drug experiences to FDA.

Written procedures for equipment cleaning and maintenance are absent, and cleaning validation has not been performed. There is no written stability testing program, and no scientific data supports assigned beyond-use dates or shelf-life, including for products produced in advance. Reserve drug product samples are not retained under consistent labeling conditions. Finally, calibration of recording devices is not done at suitable intervals; specifically, calibration weights for scales used in component weighing are not certified.

Company
Transdermal Therapeutics Inc.
Inspection date
June 27, 2014
Product type
Drugs
Office
New Orleans District Office
Person
  • Claire M. Minden (CO CDER OMQ)
View Company Profile

ID · 1b5c45a7-4c46-4a99-a49e-898f71415bbc

Violation Codes3
FD&C Act 905(j)21 CFR 331(c)21 U.S.C. 324(a)(4)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Transdermal Therapeutics Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.